• TransThera Science (Nanjing), Inc., a clinical demand-oriented biopharmaceutical company focusing on developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases, on its approximately HK$201 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*
• TYK Medicines, Inc., a clinical-stage biopharmaceutical company committed to the development of differentiated targeted therapies to address unmet medical needs in cancer treatment, on its approximately HK$575 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.*
• Laopu Gold Co., Ltd., a Chinese heritage gold jewelry brand accredited by the China Gold Association, on its approximately HK$905 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.* 
• CMB International as sole sponsor, and other underwriters, on the approximately HK$900 million global offering and listing of Bayzed Health Group Inc., an oncology healthcare group principally engaged in the investment in and provision of medical related services in China, on the Main Board of the Hong Kong Stock Exchange.*
• CICC as sole sponsor, and other underwriters, on the approximately HK$664 million global offering and listing of Shanghai Voicecomm Information Technology Co., Ltd., a leader and pioneer in conversational AI in China providing services for enterprise-level users to improve the convenience and intelligence of their information exchange and business interactions, on the Main Board of the Hong Kong Stock Exchange.*
• Adlai Nortye Ltd., a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types, on its approximately US$97.5 million initial public offering on the Nasdaq.*

* including projects involved in prior to joining Paul Hastings